Cargando…
Immunogenicity and toxicity of AAV gene therapy
Gene transfer using adeno-associated viral (AAV) vectors has made tremendous progress in the last decade and has achieved cures of debilitating diseases such as hemophilia A and B. Nevertheless, progress is still being hampered by immune responses against the AAV capsid antigens or the transgene pro...
Autor principal: | Ertl, Hildegund C. J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411526/ https://www.ncbi.nlm.nih.gov/pubmed/36032092 http://dx.doi.org/10.3389/fimmu.2022.975803 |
Ejemplares similares
-
T Cell-Mediated Immune Responses to AAV and AAV Vectors
por: Ertl, Hildegund C. J.
Publicado: (2021) -
Editorial: Immunogenicity and toxicity of AAV gene therapy
por: Bradbury, Allison, et al.
Publicado: (2023) -
rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis
por: Shen, Weiran, et al.
Publicado: (2022) -
Corrigendum: rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis
por: Shen, Weiran, et al.
Publicado: (2023) -
Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B
por: Rogers, Geoffrey L, et al.
Publicado: (2014)